Marko Marjanovic

Marko Marjanovic

Auto-generated profile, based on publicly available information

Marko Marjanovic

Department of Medical Oncology, Oncology Institute of Vojvodina, Sremska Kamenica, Serbia

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Medicinski Pregled
Verified
Journal Article
Open access
PDF file
MMMarko Marjanovic
Marko Marjanovic
AĐAleksandar Dejan Đurić
Aleksandar Dejan Đurić
Jelena RadićJelena Radić
Jelena Radić
NPNemanja Petrovic
Nemanja Petrovic
NSNevena Stanulovic
Nevena Stanulovic
KIKresoja Milana Ignjatović
Kresoja Milana Ignjatović
Introduction. Pancreatic cancer is among the most aggressive malignancies, with a poor prognosis. The liver, peritoneum, lungs, and distant lymph nodes are the most common metastatic sites. However, metastasis of pancreatic cancer to the large bowel is extremely rare. Case Report. A 48-year-old male with pancreatic cancer underwent radical pancreatosplenectomy in August 2022, accompanied by subtotal gastrectomy, partial resection of the transverse colon, and resection with reconstruction of the splenic vein. He subsequently received six cycles of adjuvant therapy based on the 5-fluorouracil/Leucovorin protocol, which concluded in February 2023. Routine follow-ups revealed multiple liver metastases by June 2023. First-line systemic treatment with the mono-Gemcitabine protocol was initiated, but disease progression occurred after three cycles. The patient then transitioned to second-line therapy with the De Gramont/Cisplatin protocol. During the second cycle, he developed intestinal obstruction necessitating emergency surgery, during which a sigmoidostomy was performed. Intraoperative biopsy of a tumor mass in the sigmoid colon confirmed metastasis of the previously operated pancreatic ductal adenocarcinoma into the colonic wall. Conclusion. Metastasis of invasive ductal pancreatic adenocarcinoma to the colon wall, causing intestinal obstruction, is an extremely rare occurrence, with only a few cases documented in the literature. Histopathological analysis of any colonic mass in patients with a history of pancreatic ductal adenocarcinoma is crucial to differentiate between primary colorectal cancer and metastatic lesions originating from pancreatic cancer.

1 January 2025 in Archive of Oncology
Verified
Journal Article
Open access
PDF file
JPJelena Perovic
Jelena Perovic
Jelena RadićJelena Radić
Jelena Radić
AĐAleksandar Dejan Đurić
Aleksandar Dejan Đurić
MMMarko Marjanovic
Marko Marjanovic
TUTeodora Urosevic
Teodora Urosevic
BKBojana Kožik
Bojana Kožik
Background: Colorectal cancer (CRC) is one of the leading causes of cancer-related morbidity and mortality worldwide. Microsatellite instability (MSI) is a crucial biomarker with prognostic and predictive value, influencing treatment decisions in CRC. Methods: This retrospective study investigated the impact of the MSI status on clinical outcomes in 184 CRC patients treated at the Oncology Institute of Vojvodina between 2018 and 2023. The MSI status was determined using the immunohistochemical analysis of mismatch repair proteins. Results: Among the cohort, 75% of tumors were microsatellite-stable (MSS), 4.3% exhibited low MSI (MSI-L), and 20.6% displayed high MSI (MSI-H). MSI-H tumors were significantly associated with right-sided CRC, mucinous differentiation, and female gender (p<0.05). The survival analyses revealed that the MSI-H patients with stage II disease had significantly better disease-free survival (DFS) and overall survival (OS) than the MSS counterparts (p=0.024 and p=0.006, respectively). Conversely, the MSI-H status in stage II patients receiving adjuvant therapy was linked to shorter DFS (p=0.000), highlighting the limited benefit from 5-fluorouracil-based regimens. In stage III CRC, the MSI status did not significantly affect DFS or OS. Conclusion: These findings underscore the dual role of MSI as a favorable prognostic marker in early-stage CRC and a predictor of the reduced benefit from adjuvant chemotherapy in stage II disease. This study emphasizes the need for individualized treatment strategies based on the MSI status and supports the potential integration of immunotherapy in the adjuvant setting for MSI-H CRC.

1 January 2024 in Archive of Oncology
Verified
Journal Article
Open access
PDF file
AĐAleksandar Dejan Đurić
Aleksandar Dejan Đurić
ALAleksandra Lovrenski
Aleksandra Lovrenski
DSDusan Skrbic
Dusan Skrbic
Jelena RadićJelena Radić
Jelena Radić
MMMarko Marjanovic
Marko Marjanovic
Pancreatic cancer is one of the most aggressive forms of malignant disease, often with a long asymptomatic course, early metastases to distant organs and with an extremely poor prognosis. Here we present the case of a 70-year-old female patient, who was hospitalized in a pulmonology institution with a severe general condition. Due to bilateral lung changes seen on the chest radiograph, she was under suspicion for pneumonia, respiratory insufficiency and had elevated markers of inflammation. On physical examination, paraumbilically on the right, a subcutaneous swelling had been palpated with a harder consistency measuring 7 cm in diameter. She presented an ulcerated umbilicus with a purulent discharge. Nineteen hours after admission, a fatal outcome occurred and the autopsy proved an extended malignant disease (pancreatic ductal adenocarcinoma (aT3N2M1, Stage IV)) with multiple metastases. It is necessary to adhere to the differential diagnostic algorithm of bilateral lung lesions. Each umbilical nodule should arouse suspicion of the existence of malignant diseases in the abdominal-pelvic region. Therefore, it is of great importance to raise people?s awareness about taking control of their health.

1 January 2026
Verified
Journal Article
Open access
TUTeodora Urosevic
Teodora Urosevic
MMMarko Marjanovic
Marko Marjanovic
SNStela Novak
Stela Novak
AĐAleksandar Dejan Đurić
Aleksandar Dejan Đurić
BTBranislav Tusek
Branislav Tusek
NRNevena Ranđelović
Nevena Ranđelović
Background: Colorectal cancer (CRC) remains a global health problem. It is the most common malignancy of the gastrointestinal tract, with a global incidence of over 1.9 million cases, making it the third most common cause of cancer-related deaths worldwide. The incidence is increasing particularly in low- and middle-income countries and among individuals under 50 years of age, with lifestyle and environmental factors contributing to this trend-many of which affect the gut microbiome. Main body: Advances in CRC treatment have introduced immunotherapy, particularly for tumours with mismatch repair deficiency (dMMR) and high microsatellite instability (MSI-H). This review explores the symbiotic relationship between the gut microbiome and immunotherapy in CRC. The human colon harbours a complex microbiome composed of diverse microbial species and vast genetic diversity, with structural, metabolic, and immunomodulatory functions. Dysbiosis, influenced by factors such as diet and lifestyle, contributes to CRC pathogenesis through inflammation and metabolic disruptions. Immunotherapy, specifically immune checkpoint inhibitors (ICIs), has revolutionized cancer treatment by enhancing T cell-mediated immune responses against cancer cells. In CRC, ICIs have demonstrated efficacy in MSI-H/dMMR tumours that represent less than 15% of all CRC cases. Challenges persist in treating microsatellite stable (MSS) CRC in regard to immunotherapy. Emerging evidence suggests that specific gut microbiota compositions influence the response to ICIs by modulating systemic immune responses and tumour microenvironments, potentially having a key role for MSS CRC patients. Strategies to manipulate the gut microbiome, including probiotics and faecal microbiota transplantation, hold promise in augmenting immunotherapy efficacy. Conclusion: The review underscores the potential of the gut microbiome as a predictive biomarker and therapeutic target in CRC immunotherapy. Ultimately, harnessing the therapeutic potential of the gut microbiome represents a promising avenue for enhancing immunotherapy outcomes and advancing personalized medicine in CRC care.

1 January 2026 in Archive of Oncology
Verified
Journal Article
Open access
PDF file
SNStela Novak
Stela Novak
IBIvana Nebojša Kolarov Bjelobrk
Ivana Nebojša Kolarov Bjelobrk
MMMarko Marjanovic
Marko Marjanovic
TUTeodora Urosevic
Teodora Urosevic
AĐAleksandar Dejan Đurić
Aleksandar Dejan Đurić
Introduction: Breast cancer is the most common malignancy in women and a major cause of mortality worldwide. Despite advances in treatment, therapeutic resistance and disease heterogeneity continue to limit the success of existing therapeutic approaches. Therefore, the identification of novel therapeutic targets has become an important focus of contemporary research. Main body: This review summarizes the most promising novel therapeutic targets in the treatment of breast cancer, including HER3, B7-H4, CD206^{+} M2 macrophages, ROR1, and WEE1. Their biological roles in tumor progression, metastasis, immune evasion, and therapeutic resistance are discussed, together with current therapeutic strategies directed at these targets. Special attention is given to antibody–drug conjugates (ADCs), bispecific antibodies, signaling pathway inhibitors, and strategies targeting tumor microenvironment modulation. Conclusion: Current preclinical and early clinical evidence indicates that HER3, B7-H4, CD206^{+} M2 macrophages, ROR1, and WEE1 are promising therapeutic targets with the potential to improve breast cancer treatment. The further development of these strategies may help overcome therapeutic resistance and contribute to more effective, personalized treatment approaches.